• 主页
  • 查找结果
  • A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.

A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy.

The Journal of urology (2013-10-19)
Joseph R Osborne, David A Green, Daniel E Spratt, Serge Lyashchenko, Shoaib B Fareedy, Brian D Robinson, Bradley J Beattie, Manu Jain, Jason S Lewis, Paul Christos, Steven M Larson, Neil H Bander, Douglas S Scherr
摘要

In this pilot study we explored the feasibility of (89)Zr labeled J591 monoclonal antibody positron emission tomography of localized prostate cancer. Before scheduled radical prostatectomy 11 patients were injected intravenously with (89)Zr-J591, followed 6 days later by whole body positron emission tomography. Patients underwent surgery the day after imaging. Specimens were imaged by ex vivo micro positron emission tomography and a custom 3 Tesla magnetic resonance scanner coil. Positron emission tomography images and histopathology were correlated. Median patient age was 61 years (range 47 to 68), median prostate specific antigen was 5.2 ng/ml (range 3.5 to 12.0) and median biopsy Gleason score of the 11 index lesions was 7 (range 7 to 9). On histopathology 22 lesions were identified. Median lesion size was 5.5 mm (range 2 to 21) and median Gleason score after radical prostatectomy was 7 (range 6 to 9). Eight of 11 index lesions (72.7%) were identified by in vivo positron emission tomography. Lesion identification improved with increasing lesion size for in vivo and ex vivo positron emission tomography (each p <0.0001), and increasing Gleason score (p = 0.14 and 0.01, respectively). Standardized uptake values appeared to correlate with increased Gleason score but not significantly (p = 0.19). To our knowledge this is the first report of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in localized prostate cancer cases. In this setting (89)Zr-J591 bound to tumor foci in situ and positron emission tomography identified primarily Gleason score 7 or greater and larger tumors, likely corresponding to clinically significant disease warranting definitive therapy. A future, larger clinical validation trial is planned to better define the usefulness of (89)Zr-J591 positron emission tomography for localized prostate cancer.

材料
货号
品牌
产品描述

Sigma-Aldrich
锆, powder, −100 mesh
Sigma-Aldrich
锆, foil, thickness 0.1 mm, 99.98% trace metals basis
Sigma-Aldrich
锆, sponge, ≥99% trace metals basis
Sigma-Aldrich
锆, rod, diam. 6.35 mm, ≥99% trace metals basis
锆, rod, 100mm, diameter 50mm, centerless ground, 99.2%
Sigma-Aldrich
锆, powder, in water, -325 mesh, 99.5% trace metals basis (excluding Hf)
锆, foil, not light tested, 50x50mm, thickness 0.006mm, 99.2%
锆, rod, 1000mm, diameter 1.5mm, 99.2%
锆, rod, 1000mm, diameter 12.7mm, centerless ground, 99.2%
锆, rod, 1000mm, diameter 2.0mm, centerless ground, 99.2%
锆, rod, 1000mm, diameter 3.0mm, centerless ground, 99.2%
锆, rod, 1000mm, diameter 5.0mm, centerless ground, 99.2%
锆, rod, 1000mm, diameter 6.0mm, centerless ground, 99.2%
锆, rod, 1000mm, diameter 9.5mm, centerless ground, 99.2%
锆, rod, 100mm, diameter 1.5mm, 99.2%
锆, rod, 100mm, diameter 12.7mm, centerless ground, 99.2%
锆, rod, 100mm, diameter 19.0mm, centerless ground, 99.2%
锆, rod, 100mm, diameter 2.0mm, centerless ground, 99.2%
锆, rod, 100mm, diameter 3.0mm, centerless ground, 99.2%
锆, rod, 100mm, diameter 5.0mm, centerless ground, 99.2%
锆, rod, 100mm, diameter 6.0mm, centerless ground, 99.2%
锆, rod, 100mm, diameter 9.5mm, centerless ground, 99.2%
锆, rod, 200mm, diameter 1.5mm, 99.2%
锆, rod, 200mm, diameter 12.7mm, centerless ground, 99.2%
锆, rod, 200mm, diameter 19.0mm, centerless ground, 99.2%
锆, rod, 200mm, diameter 2.0mm, centerless ground, 99.2%
锆, rod, 200mm, diameter 3.0mm, centerless ground, 99.2%
锆, rod, 200mm, diameter 5.0mm, centerless ground, 99.2%
锆, rod, 200mm, diameter 6.0mm, centerless ground, 99.2%
锆, rod, 200mm, diameter 9.5mm, centerless ground, 99.2%

社交媒体

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

科研、开发、生产。

作为生命科学行业的全球领先供应商,我们致力于为科研、生物技术开发和生产,以及制药药物疗法开发和生产提供各类解决方案和服务。

© 2021年版权归德国达姆施塔特默克集团(Merck KGaA)及/或其附属公司所有。版权所有。

未经许可,严禁复制本网站上的任何资料。